These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3495213)

  • 1. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.
    Belldegrun A; Webb DE; Austin HA; Steinberg SM; White DE; Linehan WM; Rosenberg SA
    Ann Intern Med; 1987 Jun; 106(6):817-22. PubMed ID: 3495213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.
    Webb DE; Austin HA; Belldegrun A; Vaughan E; Linehan WM; Rosenberg SA
    Clin Nephrol; 1988 Sep; 30(3):141-5. PubMed ID: 3263237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.
    Belldegrun A; Webb DE; Austin HA; Steinberg SM; Linehan WM; Rosenberg SA
    J Urol; 1989 Mar; 141(3):499-503. PubMed ID: 2783983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion.
    Shalmi CL; Dutcher JP; Feinfeld DA; Chun KJ; Saleemi KR; Freeman LM; Lynn RI; Wiernik PH
    J Clin Oncol; 1990 Nov; 8(11):1839-46. PubMed ID: 2230870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
    Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
    Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.
    Onishi S; Saibara T; Fujikawa M; Sakaeda H; Matsuura Y; Matsunaga Y; Yamamoto Y
    Hepatology; 1989 Sep; 10(3):349-53. PubMed ID: 2474481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
    N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interleukin-2 immunotherapy on renal function.
    Kozeny GA; Nicolas JD; Creekmore S; Sticklin L; Hano JE; Fisher RI
    J Clin Oncol; 1988 Jul; 6(7):1170-6. PubMed ID: 3260620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA
    Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells].
    Jost LM; Gmür J; Oelz O; Sauter C; Stahel RA
    Schweiz Med Wochenschr; 1988 Feb; 119(5):137-43. PubMed ID: 3266369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
    Marcus SL; Dutcher JP; Paietta E; Ciobanu N; Strauman J; Wiernik PH; Hutner SH; Frank O; Baker H
    Cancer Res; 1987 Aug; 47(15):4208-12. PubMed ID: 3496958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
    J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
    Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
    J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.
    Denicoff KD; Rubinow DR; Papa MZ; Simpson C; Seipp CA; Lotze MT; Chang AE; Rosenstein D; Rosenberg SA
    Ann Intern Med; 1987 Sep; 107(3):293-300. PubMed ID: 3497595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.
    Rosenberg SA
    Important Adv Oncol; 1988; ():217-57. PubMed ID: 3042605
    [No Abstract]   [Full Text] [Related]  

  • 16. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
    Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells.
    van Haelst-Pisani CM; Pisani RJ; Kovach JS
    Mayo Clin Proc; 1989 Apr; 64(4):451-65. PubMed ID: 2654502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
    Topalian SL; Rosenberg SA
    Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function.
    Palmieri G; Morabito A; Lauria R; Montesarchio V; Matano E; Memoli B; Libetta C; Rea A; Merola C; Correale P
    Eur J Cancer; 1993; 29A(8):1119-22. PubMed ID: 8518023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.
    Eberlein TJ; Schoof DD; Jung SE; Davidson D; Gramolini B; McGrath K; Massaro A; Wilson RE
    Arch Intern Med; 1988 Dec; 148(12):2571-6. PubMed ID: 3264142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.